Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy)

Toxicol Pathol. 2005;33(2):292-9. doi: 10.1080/019262390908380.

Abstract

Treatment with 8-methoxypsoralen (8-MOP) and ultraviolet radiation (primarily UVA), called PUVA therapy, has been used to treat different chronic skin diseases but led to a significant increased risk for skin cancer. The National Toxicology Program (NTP) performed a study in mice treated with PUVA that showed a significant increase in squamous cell carcinomas of the skin. In the present study, we evaluated the protein expression of p53 and PCNA and DNA mutations of p53 and H-ras genes in both hyperplastic and neoplastic squamous cell lesions from the NTP study. By immunohistochemical staining, protein expression of both p53 and PCNA was detected in 3/16 (19%) of hyperplastic lesions and 14/17 (82%) of SCCs in groups treated with both 8-MOP and UVA. The mutation frequency of p53 in SCCs from mice administered 8-MOP plus UVA was 15/17 (88%) with a predominant distribution of mutations in exon 6 (14/15 - 93%). No H-ras mutations were detected in the hyperplastic lesions/tumors. The mutagenic effect of PUVA on the p53 tumor suppressor gene may lead to a conformational modification and inactivation of the p53 protein, which are considered critical steps in PUVA-induced skin carcinogenesis. The p53 mutational frequency and patterns from our study were different from those reported in human PUVA-type tumors.

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell / etiology
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • DNA Mutational Analysis
  • DNA, Neoplasm / analysis
  • Genes, p53*
  • Genes, ras*
  • Hyperplasia / genetics
  • Hyperplasia / metabolism
  • Hyperplasia / pathology
  • Immunoenzyme Techniques
  • Methoxsalen / toxicity
  • Mice
  • Mice, Nude
  • Mutation*
  • PUVA Therapy / adverse effects*
  • Proliferating Cell Nuclear Antigen / metabolism*
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Skin / metabolism
  • Skin / pathology
  • Skin Neoplasms / etiology
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • Ultraviolet Rays / adverse effects

Substances

  • DNA, Neoplasm
  • Proliferating Cell Nuclear Antigen
  • Tumor Suppressor Protein p53
  • Proto-Oncogene Proteins p21(ras)
  • Methoxsalen